Navigation Links
Cardiac Science Announces Data Connectivity with LUMEDX
Date:10/17/2007

Innovative firms partner to improve workflow and data connectivity for

Cardiac Rehabilitation

BOTHELL, Wash., Oct. 17 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac monitoring and defibrillation products, announced today that its new cardiac rehab system, Q- Tel RMS(R) 3.0, now has seamless connectivity with LUMEDX CardioWellness(TM) data management software.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO)

The integration of rehabilitation data from the Q-Tel RMS 3.0 system into CardioWellness enables the best possible treatment decisions. The combination allows caregivers to seamlessly integrate data from the Q-Tel RMS 3.0 rehabilitation system into CardioWellness, creating a comprehensive diagnosis and treatment plan tuned specifically to the patient's gender specific needs. By applying this gender-specific understanding of the patient's disease state to the rehabilitation treatment, outcomes can be improved.

"Cardiac Science is dedicated to helping its customers improve their workflows and improve access to data, facilitating the best possible treatment decisions," said Ren Mitchell, director of diagnostic marketing at Cardiac Science. "In response to feedback from clinicians, the Q-Tel RMS 3.0 features enhanced connectivity capabilities to improve rehab center workflow, while maintaining the heritage of reliability and high performance of the Q-Tel family of rehabilitation management systems. We believe that this collaboration with LUMEDX will improve patient care and better meet the needs of our customers."

"CardioWellness can help facilities grow their gender-specific cardiovascular care programs with its sophisticated database for tracking patients from risk assessment through treatment," said Randy Marc Lasnick, director of marketing at LUMEDX Corporation. "Research has shown that gender- specific care can provide patients with better outcomes. We believe that by providing a direct link between CardioWellness and Q-Tel RMS 3.0, the leading cardiac rehabilitation system, we can provide greater value to these facilities by bringing an added layer of critical rehab data into the clinical decision making process."

Frost & Sullivan, the global growth consulting company, has awarded Cardiac Science its 2007 award for Global Excellence in ECG Monitoring, recognizing Cardiac Science's superior leadership and vision to provide superior healthcare solutions in the cardiac monitoring market.

For more information about the Q-Tel RMS 3.0, please call 800.679.8703.

About LUMEDX

Founded in 1990, LUMEDX is the market leader in developing end-to-end cardiovascular information and imaging systems. Providing consulting services, training, and the CardioStar(TM) software suite-the most comprehensive suite of fully integrated cardiovascular information tools-LUMEDX delivers complete clinical and business solutions for heart centers.

About CardioWellness

CardioWellness is a comprehensive set of tools and support programs to help heart centers grow their own successful gender-specific CV centers. CardioWellness recognizes the differences in presentation, diagnostic testing, risk assessment, and outcomes for men and women. These differences are built into the way patients are diagnosed, treated, and tracked throughout the continuum of care.

About Q-Tel RMS 3.0

The Q-Tel RMS system is a state-of-the-art, comprehensive cardiac monitoring and data management system developed to meet the needs of cardiac rehabilitation programs. Designed with efficient workflow and integration to EMR and HIS systems in mind, the Q-Tel family of Rehabilitation Management Systems is designed to enable the best possible treatment decisions.

About Cardiac Science Corporation

Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor - defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China; Copenhagen, Denmark; and Manchester, United Kingdom.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that our alliance with LUMEDX will contribute to our success in the marketplace, and that our sales and profits derived from our cardiac rehabilitation and monitoring devices and our other products will increase as a result. These statements, including their underlying assumptions, are subject to risks and uncertainties and are not guarantees of future performance. Other risk factors that could cause or contribute to such varying results are described in our annual report for the year ended December 31, 2006, filed with the Securities and Exchange Commission.

The statements in this press release speak as of the date of the release, and Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Company Contact:

Mike Matysik

Cardiac Science Corporation

Sr. Vice President and CFO

425-402-2009

Investor Contact:

EVC Group, Inc.

Douglas Sherk/Jenifer Kirtland

415-896-6820

Media Contact:

EVC Group, Inc.

Jen Saunders

646-201-5431


'/>"/>
SOURCE Cardiac Science Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Gene HPA-2 Met linked to cardiac arrest
3. Defibrillators In Public Places Will Help Cardiac Patients
4. Supplement helps cardiac surgery
5. Cardiac diseases develop early
6. Latest device for cardiac revival under test
7. Bone marrow stem cells may help repair cardiac tissues
8. Heart problems detected better with a Cardiac MRI
9. Cardiac events better treated with intense cholesterol-lowering regime
10. Sudden Cardiac Death due to inherited Heart Disease
11. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: